Your browser is no longer supported. Please, upgrade your browser.
PRAH [NASD]
PRA Health Sciences, Inc.
Index- P/E47.51 EPS (ttm)3.04 Insider Own0.10% Shs Outstand64.54M Perf Week13.38%
Market Cap9.43B Forward P/E21.52 EPS next Y6.71 Insider Trans-35.86% Shs Float64.37M Perf Month15.34%
Income197.00M PEG3.12 EPS next Q1.33 Inst Own98.91% Short Float1.16% Perf Quarter31.15%
Sales3.18B P/S2.96 EPS this Y-17.40% Inst Trans0.98% Short Ratio1.66 Perf Half Y38.85%
Book/sh23.16 P/B6.23 EPS next Y14.18% ROA5.10% Target Price139.40 Perf Year53.22%
Cash/sh7.75 P/C18.62 EPS next 5Y15.23% ROE15.50% 52W Range58.67 - 155.00 Perf YTD15.06%
Dividend- P/FCF26.15 EPS past 5Y18.70% ROI9.60% 52W High-6.88% Beta1.28
Dividend %- Quick Ratio1.20 Sales past 5Y14.60% Gross Margin27.30% 52W Low146.00% ATR5.37
Employees18100 Current Ratio1.20 Sales Q/Q9.20% Oper. Margin10.30% RSI (14)66.13 Volatility3.70% 3.07%
OptionableYes Debt/Eq0.86 EPS Q/Q-32.70% Profit Margin6.20% Rel Volume3.05 Prev Close147.41
ShortableYes LT Debt/Eq0.78 EarningsFeb 25 AMC Payout0.00% Avg Volume451.17K Price144.33
Recom2.50 SMA2012.37% SMA5013.59% SMA20031.67% Volume1,375,673 Change-2.09%
Aug-10-20Downgrade BofA Securities Buy → Underperform $110 → $100
May-01-20Downgrade William Blair Outperform → Mkt Perform
Apr-13-20Downgrade Wolfe Research Outperform → Peer Perform
Jan-10-20Downgrade Goldman Buy → Neutral $130 → $120
Jan-07-20Initiated Citigroup Neutral $120
Nov-14-19Upgrade Wolfe Research Peer Perform → Outperform
Sep-19-19Initiated Goldman Buy $126
Sep-13-19Upgrade KeyBanc Capital Markets Sector Weight → Overweight
May-03-19Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Oct-09-18Initiated UBS Neutral
Oct-04-18Initiated Evercore ISI In-line
Jan-24-18Downgrade Mizuho Buy → Neutral $86
Dec-11-17Initiated Barclays Overweight $94
Dec-01-17Reiterated Mizuho Buy $82 → $87
Aug-17-17Initiated Raymond James Outperform $89
Jun-26-17Initiated BofA/Merrill Buy $89
Feb-27-17Upgrade Avondale Mkt Underperform → Mkt Perform
Feb-06-17Upgrade Credit Suisse Neutral → Outperform
Sep-06-16Downgrade UBS Buy → Neutral $50 → $55
Jun-21-16Initiated First Analysis Sec Equal-Weight $47
Mar-01-21 11:02PM  
07:32PM  
11:11AM  
08:00AM  
Feb-27-21 01:01AM  
Feb-26-21 03:26PM  
01:33PM  
10:49AM  
06:45AM  
Feb-25-21 09:51PM  
07:19AM  
Feb-24-21 02:44PM  
02:09PM  
01:42PM  
12:09PM  
11:20AM  
10:48AM  
10:43AM  
08:49AM  
07:27AM  
07:25AM  
07:13AM  
06:24AM  
06:12AM  
06:04AM  
06:00AM  
03:20AM  
01:57AM  
Feb-15-21 08:47AM  
Feb-04-21 01:01PM  
Jan-08-21 05:36AM  
Jan-07-21 07:15AM  
Dec-17-20 04:02PM  
Dec-04-20 11:31AM  
Dec-03-20 02:03AM  
Nov-30-20 01:31PM  
Nov-19-20 04:02PM  
Nov-09-20 03:06PM  
Nov-06-20 08:07AM  
Nov-05-20 10:01PM  
Nov-04-20 06:15PM  
04:01PM  
Nov-03-20 10:46AM  
Oct-28-20 12:32PM  
Oct-07-20 05:09PM  
Oct-06-20 04:02PM  
01:28PM  
Sep-21-20 06:52AM  
Sep-18-20 08:30AM  
Sep-15-20 04:02PM  
Sep-14-20 03:14PM  
Sep-09-20 06:00AM  
Sep-08-20 02:09PM  
Sep-05-20 11:31AM  
Sep-03-20 09:55AM  
Aug-12-20 03:51PM  
Aug-11-20 08:10AM  
Aug-06-20 04:55PM  
04:01PM  
Jul-30-20 12:34PM  
Jul-28-20 05:17PM  
Jul-13-20 01:34PM  
Jul-02-20 01:20PM  
Jun-18-20 08:05AM  
Jun-15-20 09:24AM  
Jun-12-20 08:05AM  
Jun-08-20 02:40AM  
May-30-20 11:31AM  
May-18-20 12:22PM  
May-04-20 09:29AM  
May-01-20 07:01PM  
Apr-30-20 07:05PM  
04:01PM  
Apr-29-20 12:10PM  
08:32AM  
Apr-23-20 12:32PM  
Apr-20-20 08:28AM  
Apr-13-20 09:42AM  
Apr-08-20 04:05PM  
Mar-26-20 02:38PM  
Mar-24-20 04:05PM  
Mar-23-20 10:12AM  
Mar-22-20 04:46PM  
Mar-21-20 11:30AM  
Mar-20-20 05:08PM  
Mar-17-20 09:00AM  
Mar-11-20 04:02PM  
Mar-10-20 06:02AM  
Feb-25-20 05:40PM  
07:27AM  
Feb-24-20 02:59PM  
09:27AM  
05:36AM  
Feb-20-20 05:45PM  
04:01PM  
Feb-13-20 12:31PM  
Feb-05-20 12:34PM  
Feb-03-20 04:01PM  
Jan-22-20 05:16PM  
Jan-08-20 01:53PM  
PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company has a partnership with The Leukemia & Lymphoma Society to launch a clinical trial for developing treatments for children with relapsed acute leukemia. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gaenzle Christopher LEVP, CAO & General CounselJan 08Sale130.043,136407,80534,500Jan 11 04:26 PM
Bonello Michael J.EVP & CFODec 17Option Exercise11.7333,372391,45454,648Dec 18 04:15 PM
Bonello Michael J.EVP & CFODec 17Sale120.1233,3724,008,64521,276Dec 18 04:15 PM
SHANNON COLINPresident & CEOAug 13Sale102.886,073624,79056,927Aug 17 04:18 PM
Bonello Michael J.EVP & CFOAug 13Sale102.882,052211,11021,276Aug 17 04:17 PM
Gaenzle Christopher LEVP, CAO & General CounselAug 13Sale102.881,364140,32837,636Aug 17 04:17 PM
Bonello Michael J.EVP & CFOApr 27Sale87.973,672323,02623,328Apr 28 04:08 PM